Tevogen Bio Inc: Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision
Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy ...
Edesa Biotech, Inc.: Edesa Biotech Reports Fiscal 1st Quarter 2025 Results
Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases ...
Oncolytics Biotech faces Nasdaq delisting over share price
SAN DIEGO and CALGARY, AB - Oncolytics Biotech Inc. (NASDAQ: NASDAQ:ONCY) (TSX: ONC), a biotechnology firm focused on immunotherapy for cancer, has received a notification from the Nasdaq regarding ...
Bio-Techne Corp. stock outperforms competitors despite losses on the day
This was the stock's seventh consecutive day of losses.
ABC15 Arizona14h
Nxu Inc. shareholders approve $323 million merger with Verde Bioresins
Nxu Inc. shareholders on Feb. 11 overwhelmingly approved a proposed $323 million merger with Verde Bioresins Inc., paving a path forward for the company that struggled to generate revenue last year.